In this issue:
Efficacy and safety of deucrictibant
Tolerability of deucrictibant among hereditary angioedema
Immunogenicity, pharmacokinetics and safety of navenibart
Adverse event reports associated with immunoglobulin use
Tezepelumab for sleep disturbances, activity levels, and physical exertion tolerance
IgE levels and their association with increased risk of noninfectious complications
Head-to-head comparison of dupilumab and tezepelumab
Outcomes of secondary transplant
Findings from a novel heterozygous mutation within the RIPK1 kinase
Clinical outcomes, safety profile and quality-of-life impact of eculizumab
Please login below to download this issue (PDF)